Efficacy, safety and tolerance of imidocarb dipropionate versus atovaquone or buparvaquone plus azithromycin used to treat sick dogs naturally infected with the Babesia microti-like piroplasm

Table 4 Baseline data (D0) recorded in dogs of the three treatment groups. Continuous variables

Variable	Treatment group	Dogs (n)	Mean ± SD	95% CI	Min-Max	P-value
Age (years)	ATO	17	4.26 ± 2.56	2.94–5.58	0.25–9	0.06
	BUP	24	3.16 ± 2.71	2.01–4.30	0.16–10
	IMI	15	2.17 ± 1.94	1.09–3.24	0.25–6
Body weight (kg)	ATO	17	15.23 ± 9.80	10.28–20.37	6.50–36	0.78
	BUP	25	16.67 ± 10.34	12.40–20.90	2.40–52
	IMI	17	17.72 ± 9.88	12.60–22.80	5.3–40
Temperature (°C)	ATO	17	38.70 ± 0.84	38.20–39.13	36.5–40.2	0.2
	BUP	25	39.00 ± 0.74	38.70–39.30	37–40.6
	IMI	17	39.10 ± 0.60	38.70–39.40	38–40
Clinical score D0	ATO	17	13.00 ± 7.82	8.90–17.02	3–27	0.85
Clinical signs (points)	BUP	25	12.40 ± 6.20	9.80–14.90	3–27
Clinical signs (points)	IMI	17	11.76 ± 5.17	9.10–14.42	7–24
Clinical score D0	ATO	17	3.23 ± 1.70	2.30–4.15	1–7	0.4
Clinicopathological abnormalities (points)	BUP	25	2.70 ± 1.30	2.16–3.27	1–5
Clinicopathological abnormalities (points)	IMI	17	2.70 ± 0.83	2.33–3.19	1–4

ISSN: 1756-3305